Obesity

Biotech Elaine Chen

STAT Plus: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

STAT Plus: UnitedHealth’s doctor empire, an FDA departure, and Viking’s obesity moves

Biotech Andrew Joseph

STAT Plus: Roche CEO explains the company’s weight loss drug strategy in crowded market

Biotech Elaine Chen

STAT Plus: Viking accelerates development of obesity drug that could rival Wegovy, Zepbound

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

JD Vance’s biotech ties, Cassava resignations, and insulin shortages

Pharma Andrew Joseph

STAT Plus: A second Roche obesity drug shows promise in early studies

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Biotech layoffs, founder-focused VC, & a big pharma exit

Pharma Matthew Herper and Elaine Chen

STAT Plus: Pfizer says it will advance once-daily GLP-1 pill after all

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

Letters to the editor Patrick Skerrett

First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more

Health Rohan Rajeev

STAT Plus: GLP-1s associated with lower risk of 10 obesity-related cancers, study shows

Biotech Elaine Chen

STAT Plus: Study links Ozempic to higher risk of eye condition that can cause vision loss

First Opinion Alissa S. Chen

Medicare should wait on approving coverage for new obesity drugs

First Opinion Annette Ansong, Rachel Bond, and Tiffany Powell-Wiley

Medicare’s Part D policy is blocking progress needed to achieve Black health equity

Politics Rachel Cohrs Zhang, John Wilkerson, and Lizzy Lawrence

STAT Plus: House panel passes bills to expand Medicare obesity drug coverage, cancer screening

The Readout LOUD Allison DeAngelis and Brittany Trang

Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

Politics Rachel Cohrs Zhang

STAT Plus: House panel proposes new strategy for Medicare to cover weight loss drugs Wegovy, Zepbound

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests

Biotech Elaine Chen

STAT Plus: Zealand’s amylin-targeting drug shows early potential in obesity

Health Elizabeth Cooney

To treat obesity in children, task force favors behavioral therapy over drugs like Wegovy

The Readout Adam Feuerstein

STAT Plus: A biotech’s binary bet ends badly

Politics Rachel Cohrs Zhang

STAT Plus: Novo Nordisk CEO agrees to Bernie Sanders’ demand to testify on Ozempic, Wegovy prices

The Readout LOUD Adam Feuerstein and Allison DeAngelis

STAT Plus: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)

First Opinion Paul von Hippel

What happened to obesity after Chile slew Tony the Tiger?

The Readout Elaine Chen

STAT Plus: What do Parkinson’s and obesity have in common?

Health tech Brittany Trang

STAT Plus: Google’s Verily to offer GLP-1 drugs through Lightpath, its retooled chronic care app

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices

First Opinion W. Franklyn Richardson

How faith leaders like me can help address America’s obesity epidemic

First Opinion Jayasree K. Iyer

Obesity drugs pose a big challenge for health care equity